Vincent Goëb
Vincent Goëb is an expert in Rheumatology at Centre Hospitalier Universitaire Amiens-Picardie (France). As of September 2026, ScienceLeadR ranks Vincent Goëb in the top 1% of experts worldwide for Arthritis. Vincent Goëb has authored 232 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 7 of them ongoing. SLR score: 789 (community average: 125). How the SLR is computed.
LeadR Profile
Rheumatology
Subspecialties: Dermatology - Infectiology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 232
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Vulvar findings and sexual dysfunction in women with systemic sclerosis. PMID 42382269 — sclerosis, carcinoma, squamous cell, lichen sclerosus et atrophicus, vulvodynia, scleroderma, systemic | JAAD Int | 2026 | 0 |
| Relevance of Systematic Pre-Biologic Infectious Screening in Chronic Inflammatory Rheumatic Diseases: A Retrospective Single-Center Study. PMID 42355798 — latent tuberculosis, hepatitis c antibodies, radiography, rheumatic diseases, tuberculosis, viruses, therapeutics, biological therapy, infections, hepatitis | J Clin Med | 2026 | 0 |
| Systematic skin cancer screening in patients treated with biologics for chronic inflammatory rheumatic diseases: an 11-year experience. PMID 42025014 — skin, sexually transmitted diseases, incidence, melanoma, neoplasms, arthritis, propensity score, rheumatic diseases, risk factors, arthritis, rheumatoid, therapeutics, dermatology, skin neoplasms | Ann Dermatol Venereol | 2026 | 0 |
| Condensation of the lower part of the iliac bone. PMID 41825770 — joint diseases | Joint Bone Spine | 2026 | 0 |
| Artificial Intelligence in Rheumatology: From Algorithms to Clinical Impact in Osteoporosis and Chronic Inflammatory Rheumatic Diseases. PMID 41598430 — arthritis, psoriatic, rheumatology, intelligence, algorithms, rheumatic diseases, machine learning, osteoporosis, arthritis, rheumatoid, diagnosis, therapeutics, learning, artificial intelligence | J Clin Med | 2026 | 0 |
Clinical Studies 14
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| HLA B Leader in Patients With Psoriatic Arthritis NCT07718815 — genes, genetic research, arthritis, psoriatic, blood, arthritis, hla-b27 antigen, research, hla-b antigens, psoriasis, hematologic tests, transplantation | N/A | Recruiting | 2025 |
| Strategies for zoledronic acid post denosumab discontinuation in postmenopausal osteoporosis 2024-511871-13-00 — zoledronic acid, denosumab, osteoporosis, osteoporosis, postmenopausal, therapeutics | Phase 4 | Recruiting | 2025 |
| JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients 2023-509788-25-00 — arthritis, arthritis, rheumatoid, drug tapering, therapeutics, janus kinase inhibitors | Phase 4 | Recruiting | 2025 |
| StrAtegies For Zoledronic Acid Post dEnosumab Discontinuation in Postmenopausal oSTeoporosis NCT06767150 — zoledronic acid, denosumab, osteoporosis, osteoporosis, postmenopausal, therapeutics, osteoporotic fractures | Phase 4 | Recruiting | 2025 |
| JAK Inhibitor Dose TAPering Strategy Study NCT06687551 — laboratories, arthritis, arthritis, rheumatoid, drug tapering, therapeutics, janus kinase inhibitors, random allocation | Phase 4 | Recruiting | 2025 |
LeadR Networks
Main global connection map